Phase I Clinical Evaluation of a Neutralizing Monoclonal Antibody Against Epidermal Growth Factor Receptor in Advanced Brain Tumor Patients: Preliminary Study

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Hybridoma

• Publication date

  2001-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/02724570152057634PMID 11394532
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intralesional administration of I-131 labelled monoclonal antibodies in the treatment of malignant gliomas

  2005cited by this paper
• Phenotype vs Genotype in the Evolution of Astrocytic Brain Tumors

  2000cited by this paper
• Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner

  2000cited by this paper
• Tumor angiogenesis: past, present and the near future.

  2000cited by this paper
• Genetic profile of gliosarcomas.

  2000cited by this paper
• Inhibition of phospholipase C-gamma1 activation blocks glioma cell motility and invasion of fetal rat brain aggregates.

  1999cited by this paper
• Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas.

  1999cited by this paper
• Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.

  1999cited by this paper
• Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas

  1998cited by this paper
• Establishing a Link between Oncogenes and Tumor Angiogenesis

  1998cited by this paper
• Comparison between fluorescence in situ hybridization and classical cytogenetics in human tumors.

  1998cited by this paper
• [Clinical and pathological significance of p53 gene mutation in human cerebral glioblastoma multiforme].

  1998cited by this paper
• Comparative analysis of proliferating cell nuclear antigen and epidermal growth factor receptor expression in glial tumours: correlation with histological grading.

  1998cited by this paper
• Association of EGFR Gene Amplification and CDKN2 (p16/MTS1) Gene Deletion in Glioblastoma Multiforme

  1997cited by this paper
• Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma

  1997cited by this paper
• Growth factor profiles of human gliomas. Do non-tumour cells contribute to tumour growth in glioma?

  1997cited by this paper
• Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.

  1997cited by this paper
• Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s).

  1997cited by this paper
• Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

  1997cited by this paper
• A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas.

  1996cited by this paper
• The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates.

  1996cited by this paper
• Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas.

  1996cited by this paper
• The use of epidermal growth factor receptor-425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of patients with high grade gliomas of the brain.

  1996cited by this paper
• Epidermal Growth Factor Receptor 425 Monoclonal Antibodies Radiolabeled with Iodine-125 in the Adjuvant Treatment of High-Grade Astrocytomas

  1995cited by this paper
• Utilization of 125I monoclonal antibody in the management of primary glioblastoma multiforme

  1995cited by this paper
• Indium‐111‐labeled anti‐egfr‐425 scintigraphy in the detection of malignant gliomas

  1994cited by this paper
• Harmonisation in Pharmacovigilance

  1994cited by this paper
• Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial.

  1992cited by this paper
• A new monoclonal antibody for detection of EGF‐receptors in western blots and paraffin‐embedded tissue sections

  1992cited by this paper
• Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. A pilot study.

  1990cited by this paper
• Iodine125 labeled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas. A pilot study.

  1990cited by this paper
• Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. A pilot study.

  1989cited by this paper
• Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase.

  1989cited by this paper
• Expression of an altered epidermal growth factor receptor by human glioblastoma cells.

  1988cited by this paper
• Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen.

  1985cited by this paper
• Expression of epidermal growth factor receptors in human brain tumors.

  1984cited by this paper

• Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

  2022cites this paper
• EGFR, the Lazarus target for precision oncology in glioblastoma.

  2022cites this paper
• Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study

  2021cites this paper
• High Grade Meningiomas: Current Therapy Based on Tumor Biology

  2021cites this paper
• Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours

  2020cites this paper
• En Plaque Meningiomas: A Narrative Review

  2019cites this paper
• Emerging Medical Treatments for Meningioma in the Molecular Era

  2018cites this paper
• A novel recombinant anti‐epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model

  2017cites this paper
• Inhibition activity of a disulfide-stabilized diabody against basic fibroblast growth factor in lung cancer

  2017cites this paper
• A novel recombinant anti-EGFR peptide vaccine capable of active immunization and reduction of tumor volume in mice model Running title : A novel recombinant EGFR peptide vaccine Specified field : immunology

  2017cites this paper
• Radiolabeled Antibody‐Based Imaging in Clinical Oncology

  2016cites this paper
• TARGETED THERAPY – A HOPE FOR MALIGNANT GLIOMA TREATMENT

  2016cites this paper
• Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013

  2016cites this paper
• Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)

  2016cites this paper
• Innovative Therapeutic Strategies in the Treatment of Meningioma.

  2015cites this paper
• Quimioterapia de rescate con cisplatino, vincristina y nimotuzumab en el tratamiento de pacientes pediátricos con tumores cerebrales en primera recaída o refractarios

  2013cites this paper
• Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.

  2013cites this paper
• Treatment of children with high grade glioma with nimotuzumab: A 5-y institutional experience

  2013cites this paper
• Detecting and Treating Cancer with Nanotechnology

  2012cites this paper
• Nimotuzumab treatment of malignant gliomas

  2012cites this paper
• Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies

  2012cites this paper
• Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer

  2012cites this paper
• Resultado preliminar del tratamiento con nimotuzumab en 3 pacientes con meningiomas recurrentes

  2011cites this paper
• Nimotuzumab for pediatric diffuse intrinsic pontine gliomas

  2011cites this paper
• This information is current as Receptor Activation with a Specific Antibody Blockade of Epidermal Growth Factor Induction of Immunogenic Apoptosis by

  2011cites this paper
• Medical treatment of recurrent meningiomas

  2011cites this paper
• Medical therapies for meningiomas

  2010cites this paper
• Combination Effect of Cetuximab with Radiation in Colorectal Cancer Cells

  2010cites this paper
• Experimental approaches for the treatment of malignant gliomas.

  2010cites this paper
• Combination Effect of Nimotuzumab with Radiation in Colorectal Cancer Cells

  2010cites this paper
• CHAPTER 56 – Chemotherapy and Experimental Medical Therapies for Meningiomas

  2010cites this paper
• Etude des médiateurs lipidiques dans la pathologie des méningiomes et des gliomes

  2010cites this paper
• Advances in meningioma therapy

  2009cites this paper
• Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007.

  2009cites this paper
• Nimotuzumab in pediatric glioma.

  2009cites this paper
• Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma

  2008cites this paper
• Emerging Treatments and Gene Expression Profiling in High-Risk Medulloblastoma

  2007cites this paper
• Systemic and skin toxicity in cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab

  2007cites this paper
• Emerging monoclonal antibody therapies for malignant gliomas

  2007cites this paper
• Rational bases for the development of EGFR inhibitors for cancer treatment.

  2007cites this paper
• Targeted drug therapy for meningiomas.

  2007cites this paper
• Inhibiting kinases in malignant gliomas

  2007cites this paper
• Novel therapies for meningiomas

  2006cites this paper
• Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial

  2006cites this paper
• Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant

  2006cites this paper
• Clinical implications of the mechanism of epidermal growth factor receptor inhibitors

  2006cites this paper
• Epidermal growth factor inhibition in solid tumours

  2005cites this paper
• Transient expression in tobacco leaves of an aglycosylated recombinant antibody against the epidermal growth factor receptor.

  2005cites this paper
• Current Methods for Detecting Antibodies against Erythropoietin and Other Recombinant Proteins

  2005influential citation
• Small molecule and monoclonal antibody therapies in neurooncology.

  2005cites this paper
• Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience.

  2005cites this paper
• Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials.

  2004cites this paper
• EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS: NOVEL THERAPY FOR THE TREATMENT OF HIGH-GRADE GLIOMAS

  2004cites this paper
• Multiple dose toxicity study of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 intravenously administered to Cercopithecus aethiops sabaeus monkeys

  2004cites this paper
• Immunization with a plant-produced colorectal cancer antigen

  2004cites this paper
• Targeted molecular therapy for malignant gliomas

  2004cites this paper
• [Radioimmunolocalization of head and neck tumors with a new monoclonal antibody against the EGF receptor. Preliminary results].

  2004cites this paper
• Perspectives of Cellular and Molecular Neurosurgery.

  2004cites this paper
• Radioinmunolocalización de tumores de cabeza y cuello con un nuevo anticuerpo monoclonal contra el receptor del EGF. Resultados preliminares

  2004cites this paper
• Perspectives of Cellular and Molecular Neurosurgery

  2004cites this paper
• Recent advances in the molecular genetics of primary gliomas

  2003cites this paper
• Interleukin-13 Receptor-Directed Cytotoxin for Malignant Glioma Therapy: From Bench to Bedside

  2003cites this paper
• Principles of Cancer Immunotherapy

  2003cites this paper
• Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer

  2003cites this paper
• An update on epidermal growth factor receptor inhibitors

  2002cites this paper